Description

4-Quinazolinamine, n-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-[[(3R)-Tetrahydro-3-Furanyl]Oxy]- is a high-purity, advanced pharmaceutical intermediate of significant interest in modern drug discovery. This compound is valued for its complex heterocyclic structure, which serves as a critical building block in the synthesis of targeted therapeutic agents. It is primarily sought by research institutions and pharmaceutical manufacturers engaged in the development of novel small-molecule drugs, particularly in oncology and other specialized therapeutic areas.

Application

• Pharmaceutical Intermediate: A key synthetic precursor in the research and development of novel kinase inhibitors and other targeted cancer therapies.
• Chemical Synthesis Building Block: Used in medicinal chemistry for structure-activity relationship (SAR) studies and lead optimization programs.
• Biochemical Research: Serves as a reference standard or probe molecule in biochemical assays to study specific enzyme interactions and pathways.
• Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for custom synthesis and scale-up projects under cGMP conditions.
• Academic Research: Utilized in university and institutional laboratories for exploratory research in organic chemistry and drug design.

Basic Information

Product Name	4-Quinazolinamine, n-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-[[(3R)-Tetrahydro-3-Furanyl]Oxy]-
CAS No.	402855-07-6
Molecular Formula	C18H14ClFN4O4
Molecular Weight	404.78 g/mol
Synonyms	N-(3-Chloro-4-fluorophenyl)-6-nitro-7-[(3R)-oxolan-3-yl]oxy]quinazolin-4-amine; (R)-N-(3-Chloro-4-fluorophenyl)-6-nitro-7-(tetrahydrofuran-3-yloxy)quinazolin-4-amine; 4-Amino-N-(3-chloro-4-fluorophenyl)-6-nitro-7-[(3R)-tetrahydro-3-furanyl]oxy]quinazoline; 402855-07-6; 4-Quinazolinamine derivative; Advanced kinase inhibitor intermediate; Tetrahydrofuran-containing quinazoline.
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to stringent quality protocols to ensure batch-to-batch consistency and reliability for critical research and development work. Each lot is supported by a comprehensive Certificate of Analysis (COA) detailing purity, identity, and impurity profiles. We employ validated analytical methods, including HPLC, NMR, and MS, to confirm chemical structure and meet the exacting standards required for pharmaceutical applications. Specifications can be aligned with cGMP guidelines for projects requiring regulatory support.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (typically 15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed after opening to prevent degradation from atmospheric moisture. For long-term storage, consider using desiccants.

Specification

Item	Specification
Appearance	Yellow to light brown solid powder
Identification (HPLC)	Retention time corresponds to reference standard
Identification (IR)	Spectrum matches reference
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm
Single Unknown Impurity (HPLC)	≤ 0.5%
Total Impurities (HPLC)	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.